Stay updated on Relatlimab Plus Nivolumab in Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Relatlimab Plus Nivolumab in Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Relatlimab Plus Nivolumab in Gastric Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    An NIH-wide notice announces the transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision changes from v3.7.1 to v3.7.2, while the study page remains unavailable with a 403 error.
    Difference
    1%
    Check dated 2026-10-20T17:14:15.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T18:51:44.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the study content with an access-denied message. The page chrome (header/footer) remains visible, indicating the record cannot be loaded at this time.
    Difference
    19%
    Check dated 2026-09-22T23:31:05.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The page shows an updated platform revision from v3.6.6 to v3.7.0, indicating a software update. This update represents maintenance and potential UI or bug fixes and does not modify the study data or listed details.
    Difference
    0.0%
    Check dated 2026-09-15T22:09:56.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.5 to v3.6.6, indicating a minor software revision to the page. No content or user-facing features appear to be altered.
    Difference
    0.0%
    Check dated 2026-09-01T18:23:17.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The study's identifiers now include a line for '2018 ( U.S. NIH Grant/Contract )', indicating NIH funding for the trial.
    Difference
    0.0%
    Check dated 2026-08-25T19:48:53.000Z thumbnail image

Stay in the know with updates to Relatlimab Plus Nivolumab in Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Relatlimab Plus Nivolumab in Gastric Cancer Clinical Trial page.